Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSThe first documented case of Boerhaave's syndrome tied to a GLP-1 drug followed a restart at the maximum 2.4 mg dose with no titration, a flag for the common pause-and-resume pattern.
In 115 patients with gut and pancreatic neuroendocrine tumors, a newer DOTATOC PET scan reclassified more than half of the patients ruled ineligible on the older octreotide scan as eligible for peptide receptor radionuclide therapy. The camera, not the disease, moved the gate.
A lentivirus carrying the GLP-1 gene regrew insulin-making beta cells in diabetic rats. The newborn pancreas rebuilt itself; the adult one only partly recovered, and digestive-enzyme cells stayed out of it entirely.
The approved KRAS drugs were built for the G12C mutation. A computational screen turned up a peptide that binds G12V, the version that drives many colorectal tumors, and a knockdown test argues the effect runs through the target.
AL-VI10, the first amphibian-derived peptide shown to act on blood-vessel aging, reversed senescence signs in old mice and human endothelial cells. Block one enzyme, SIRT1, and the benefit faded, which turns a vague antioxidant story into a specific, testable pathway.
A retrospective database study tied GLP-1 drugs to a 63 percent lower death rate in cirrhosis patients, with tight confidence intervals. The size of the mortality signal, and a complications result at war with it, are the reasons to distrust it rather than headline it.
In the first head-to-head trial, a self-assembling peptide sprayed onto a fresh ooze after a bile-duct cut sealed it on the first try in 92 percent of patients, against 77 percent for the standard balloon, and needed a backup device a third as often.
MOTS-c, a peptide cells make from their own mitochondrial DNA, preserved leg muscle in mice with cancer cachexia by quieting the genes that take muscle apart. It did not stop the weight or fat loss, and the work is still in mice.
B7-H3 is on many solid tumors and the subject of a wave of antibody-drug conjugates and CAR-T trials, but those only help patients whose tumors carry it. A Fudan team built a gallium-68 bicyclic peptide PET tracer whose signal tracked B7-H3 levels in mice, a step toward imaging who to treat. Preclinical.
Novo Nordisk shut down EVOKE and EVOKE+ when semaglutide missed its week-104 endpoint. A single-author paper re-ran the unanalyzed week-130 and 156 data and found a late signal. The caveats, post-hoc tests on summary statistics by a conflicted author, are heavy.
A de novo macrocyclic peptide blocked the Wnt5a-to-ROR1 handshake and halted DIPG cells, while equally tight-binding relatives had no effect. Cell-line only, but it gives an incurable childhood brainstem tumor its first validated receptor target.
A target trial emulation of 3,572 pregnancies found that continuing a GLP-1 drug into the first trimester did not clearly raise the risk of pregnancy loss, growth problems, or birth defects, but the confidence intervals were wide enough that a real increase could not be ruled out.
A meta-analysis of four trials and 655 patients found CGRP monoclonal antibodies cut cluster headache attacks by 0.81 per week, an effect too small and too uncertain to call, with a placebo response between 27 and 53 percent doing much of the work.
A target trial emulation of 161,798 obese, nondiabetic adults found GLP-1 users had a hazard ratio of 0.59 for obesity-associated cancers, about 41 percent fewer diagnoses. The protection held in every subgroup but one.
Petrelintide's full Phase 2 data landed at the diabetes meeting. The weight loss trailed the incretins, but vomiting came in below the placebo arm, which is the whole case for the amylin class.